concurrent pembrolizumab and chemotherapy in classical hodgkin lymphoma
Published 2 years ago • 173 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
4:18
pembrolizumab monotherapy for older/abvd-ineligible patients with hodgkin lymphoma
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
1:39
pembrolizumab & ice for hodgkin lymphoma
-
1:43
keynote-667: pembrolizumab for children and young adults with classical hodgkin lymphoma
-
1:58
outcomes of patients with hodgkin lymphoma undergoing allohsct after pembrolizumab therapy
-
0:49
pembrolizumab combined with favezelimab for heavily pretreated classical hodgkin lymphoma
-
10:43
immunotherapy and lymphoma treatment
-
5:29
developing new prognostic scores in hodgkin lymphoma
-
6:24
tnb-486: interim results of a cd19/cd3 t-cell engager in r/r follicular lymphoma
-
2:57
favezelimab plus pembrolizumab in transplant-ineligible patients with r/r classical hodgkin lymphoma
-
4:31
concurrent pembrolizumab with avd for untreated classical hodgkin lymphoma
-
1:10
avenue: avelumab for classical hodgkin lymphoma
-
0:35
nivolumab and pembrolizumab and the current treatment landscape for hodgkin lymphoma
-
2:42
the current role of chemotherapy in the treatment of hodgkin lymphoma & the impact of novel agents
-
3:07
keynote-204 in r/r classical hodgkin lymphoma
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
6:16
overview of novel restore and target treatment approach to classical hodgkin lymphoma
-
1:09
novel immunotherapy combinations in hodgkin lymphoma
-
1:17
keynote-667: pembrolizumab plus copdac-28 for high-risk chl with slow early response to oepa
-
2:39
new findings and challenges in the use of immunotherapy in hodgkin lymphoma
-
5:01
relapsed & refractory classic hodgkin lymphoma